Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity Drugs

AstraZeneca Plc (NASDAQ:AZN) on Thursday said it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500 million to support the enhanced manufacturing capability of a broader range of medicines, including cancer treatments.

Benzinga

NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

The Guardian - UK

AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension

On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Bax24 Phase 3 trial to evaluate the safety, tolerability, and the effect of 2mg baxdrostat versus placebo.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases

Algen Biotechnologies, a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NASDAQ:AZN) to accelerate the discovery of novel therapeutic targets in immunology.

Benzinga

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy

AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial.

Benzinga

FTSE 100 hits another high despite concerns over US government shutdown

Drug companies AstraZeneca, Hikma Pharmaceuticals and GSK were all big risers.

Evening Standard

The UK must invest in medicines – but not at any price

The UK’s science minister, Sir Patrick Vallance, has sounded the alarm over the country’s declining investment in medicines. He warned that the NHS risks losing out on important treatments and the country could lose its place at the cutting edge of medical research if spending does not recover. It comes…

The Conversation

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca’s listing rejig spells long-term danger for London

It’s not skipping off entirely to New York, but pharma giant sets a worrying precedent for UK stock market

The Guardian - UK

AstraZeneca Moves From ADRs To NYSE Listing

The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE).

Benzinga

AstraZeneca will list shares directly in New York, but isn't leaving the UK

Amid concerns it might leave the UK, the pharma giant reaffirmed its commitment to the country, keeping its headquarters, primary listing, and tax base there.

Euronews

Emma Walmsley steps down as CEO of GSK as pharmaceutical industry faces upheaval

The drug and vaccine maker is a £60bn firm – one of the biggest in the UK

The Independent UK

GSK Switches CEO As Trump Tariffs Test Pharma

British pharmaceutical giant GSK on Monday said longtime chief executive Emma Walmsley will be replaced by its chief commercial officer in January, as the company navigates US tariffs on the sector.

International Business Times

AstraZeneca to upgrade US listing in ‘knock-back for London’

UK’s biggest drugmaker will put its US shares on a par with its London-based stock but says HQ will stay in Cambridge

The Guardian - UK

AstraZeneca to overhaul US listing but remain on London market and keep UK HQ

The Cambridge-based firm is set to directly list its ordinary shares on the New York Stock Exchange amid an increased focus on the US.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Your AstraZeneca Medicine Could Be Cheaper As Much As 70%

AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery.

The Independent UK

NHS facing ‘critical threat’ after Trump pressure to hike drug prices

NEWS ANALYSIS: Drug prices in the UK could rise amid 100 per cent tariffs on branded medicines and pressure from US President Donald Trump to stop ‘global freeloading’, Alicja Hagopian reports

Evening Standard

Brighter US outlook fires up European stocks

The FTSE 100 index closed up 70.85 points, or 0.8%, at 9,284.83.

The Guardian - UK

UK fuel retailers accused of ‘ripping off’ motorists at the pumps; markets shrug off latest Trump tariffs – as it happened

Rolling coverage of the latest economic and financial news

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

Benzinga

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Benzinga

AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial

AstraZeneca Plc (NASDAQ:AZN) released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).

The Guardian - UK

UK set on resolving standoff with big pharma, science minister says

Patrick Vallance says relations must improve and NHS has to reverse decline in drugs investment

Evening Standard

UK ‘difficult’ operating environment says Merck boss after £1bn London site axed

Last week, Merck’s business in the UK and Europe, MSD, said it will move its life sciences operation to the US, impacting around 125 British jobs.

The Guardian - UK

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK

The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise

Editorial: The industry’s retreat from the UK reflects a deeper shift about how Beijing is rewriting the rules of innovation

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the London Stock Exchange

180 stories

Amgen

162 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.